PCM
CERE

PenderFund Capital Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

PenderFund Capital Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-8,600
Closed -$481K – 166
2024
Q2 		$481K Sell
8,600
-8,200
-49% -$341K 0.13% 60
2024
Q1 		$962K Buy
16,800
+7,400
+79% +$311K 0.25% 44
2023
Q4 		$528K Buy
+9,400
New +$270K 0.17% 54

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

PenderFund Capital Management's CERE Position: Q3 2024 in Review

PenderFund Capital Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 8,600 shares — an estimated $481K sold.

PenderFund Capital Management first reported a position in CERE in Q4 2023 and held it in 3 quarters. The position peaked at $962K in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • PenderFund Capital Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • PenderFund Capital Management sold 8,600 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $481K.
  • PenderFund Capital Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 3 quarters.
  • PenderFund Capital Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $962K in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on PenderFund Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.